We are live on ! Find out more
DRUG

Bright Minds Biosciences
DRUG

94 hedge funds and large institutions have $670M invested in Bright Minds Biosciences in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

314% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 7

200% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 15

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

30% more capital invested

Capital invested by funds: $515M → $670M (+$155M)

27% more funds holding

Funds holding: 74 → 94 (+20)

9.77% more ownership

Funds ownership: 84.64% → 94.41% (+9.8%)

Holders
94
Holders Change
+20
Holders Change %
+27.03%
% of All Funds
1.16%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
29
Increased
45
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$39.6M
2
DM
Deerfield Management
New York
+$22.8M
3
RCM
RA Capital Management
Massachusetts
+$21.3M
4
BlackRock
BlackRock
New York
+$18.3M
5
GPP
Great Point Partners
Connecticut
+$17.7M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$11.4M
2
SC
Stempoint Capital
New York
-$7.6M
3
PA
Perceptive Advisors
New York
-$5.78M
4
SCM
Superstring Capital Management
New York
-$2.73M
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$93.5M +$10.3M +128,329 +11%
CAM
2
Cormorant Asset Management
Massachusetts
$77.3M – – –
BlackRock
3
BlackRock
New York
$45.4M +$18.3M +227,890 +58%
VC
4
Vivo Capital
California
$40.7M +$4.47M +55,555 +11%
B
5
Braidwell
Connecticut
$39.4M +$17.3M +215,350 +66%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$36.2M +$8.05M +100,000 +25%
VPC
7
Vestal Point Capital
New York
$35.9M +$39.6M +492,319 New
DCM
8
Driehaus Capital Management
Illinois
$31.6M +$13.1M +162,874 +60%
PA
9
Perceptive Advisors
New York
$27.5M -$5.78M -71,746 -16%
Balyasny Asset Management
10
Balyasny Asset Management
Illinois
$21.7M +$5.78M +71,746 +32%
DM
11
Deerfield Management
New York
$20.7M +$22.8M +283,000 New
RCM
12
RA Capital Management
Massachusetts
$19.3M +$21.3M +265,000 New
GPP
13
Great Point Partners
Connecticut
$16.1M +$17.7M +220,000 New
MB
14
MPM BioImpact
Massachusetts
$15.5M -$1.45M -17,972 -8%
IC
15
Ikarian Capital
Texas
$12.2M +$582K +7,226 +5%
Wellington Management Group
16
Wellington Management Group
Massachusetts
$9.97M +$9.9M +122,989 +899%
Morgan Stanley
17
Morgan Stanley
New York
$9.69M +$51.7K +642 +0.5%
EAM
18
Eventide Asset Management
Massachusetts
$9.49M +$2.17M +27,000 +26%
SGM
19
Seven Grand Managers
New York
$8.76M +$5.63M +70,000 +140%
ACP
20
Acuta Capital Partners
California
$8.17M +$2.22M +27,519 +33%
State Street
21
State Street
Massachusetts
$7.9M +$2.49M +30,961 +40%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$6.47M +$2.03M +25,170 +40%
SCM
23
Sio Capital Management
New York
$6.28M +$338K +4,200 +5%
Goldman Sachs
24
Goldman Sachs
New York
$5.43M +$2.08M +25,822 +53%
BGI
25
B Group Inc
Texas
$4.93M +$5.43M +67,500 New
1
2 3 4 5

DRUG Hedge Fund Activity: Q1 2026 in Review

94 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2026, worth a combined $670M — up 30% from $515M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new DRUG positions and 7 closed out — a net gain of 22 holders — while 45 added to existing stakes and 15 trimmed.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $39.6M. The largest seller was Millennium Management, cutting an estimated $11.4M.

  • 94 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2026, up from 74 in Q4 2025.
  • Funds reported $670M of Bright Minds Biosciences stock for Q1 2026, up 30% quarter-over-quarter.
  • 29 funds opened new Bright Minds Biosciences positions in Q1 2026 and 7 closed out, a net change of +22 holders.
  • The largest Bright Minds Biosciences buyer in Q1 2026 was Vestal Point Capital, an estimated $39.6M added.
  • The largest Bright Minds Biosciences seller in Q1 2026 was Millennium Management, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2026.